Twist Bioscience Corp
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other information
Rule 10b5-1 Trading Plans
On February 26, 2024, William Banyai, the Company's Senior Vice President of Advanced Development and General Manager of Data Storage, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”). Dr. Banyai's 10b5-1 Plan provides for the potential sale of up to 279,027 shares of the Company’s common stock and will expire on the earlier of May 30, 2025 and the date when all shares under the 10b5-1 Plan are sold.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.